BioMarin Pharmaceutical (BMRN)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$66.53+0.15%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · BMRN
Next print, the company's guidance track record, and the earnings events we've seen in the last few years.
Likelihood the company beats analyst consensus on its next print. Read from its own beat history plus how sector peers have been reporting. Not a price-direction call: a serial beater often has the beat already priced in.
Prints it beat consensus, recent quarters.
Indicative, not a guarantee. Base rate ~71%.
Industry peers that beat since this name last reported.
Management's most recent EPS guidance action.
expected = 0.35*own_median(9.8) + peer(0.2*0.0) + term(-3.0) → 0.45% (capped ±15.0)
in 50 days
Average absolute move on past earnings days.
Annualized: recent baseline volatility.
Of the last 0 guided quarters.
Actual vs. guided EPS, signed.
Excess return vs. sector ETF, day after print.
Earnings prints and pre-announcements detected in the SEC filing stream.
Results of Operations and Financial Condition. On August 6, 2026, BioMarin Pharmaceutical Inc. (the Company) announced financial results for its second quarter ended June 30, 2026. The Company’s press release issued on August 6, 2026 is attached hereto as Exhibit 99.1 and is incorporated by reference herein. The information in this Form 8-K, including in the press release furnished as Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of…
Quarterly EPS and revenue actuals vs. consensus across the last eight quarters (including beat/miss size and the forward consensus heading into the next print) are on the way.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Results of Operations and Financial Condition. On May 4, 2026, BioMarin Pharmaceutical Inc. (the Company) announced financial results for its first quarter ended March 31, 2026. The Company’s press release issued on May 4, 2026 is attached hereto as Exhibit 99.1 and is incorporated by reference herein. The information in this Form 8-K, including in the press release furnished as Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934,…
Results of Operations and Financial Condition. On February 23, 2026, BioMarin Pharmaceutical Inc. (the Company) announced financial results for its fourth quarter ended December 31, 2025. The Company’s press release issued on February 23, 2026 is attached hereto as Exhibit 99.1 and is incorporated by reference herein. The information in this Form 8-K, including in the press release furnished as Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Excha…
Results of Operations and Financial Condition. On January 26, 2026, BioMarin Pharmaceutical Inc. (BioMarin or the company) announced that it estimates having generated approximately $3.2 billion in total revenues (unaudited) for the year ended December 31, 2025, including approximately $920 million in revenues (unaudited) for the year ended December 31, 2025 from sales of VOXZOGO ® , and that, as of December 31, 2025, it had approximately $2.1 billion in cash, cash equivalents and investments…
Results of Operations and Financial Condition. On January 12, 2026, BioMarin Pharmaceutical Inc. (BioMarin or the company) presented a business update at the 44th Annual J.P. Morgan Healthcare Conference (the Presentation), during which BioMarin disclosed that based on preliminary results BioMarin estimates that it generated approximately $3.2 billion in total revenues (unaudited) for the year ended December 31, 2025, including approximately $920 million in revenues (unaudited) for the year e…
Results of Operations and Financial Condition. On October 27, 2025, BioMarin Pharmaceutical Inc. (the Company) announced financial results for its third quarter ended September 30, 2025. The Company’s press release issued on October 27, 2025 is attached hereto as Exhibit 99.1 and is incorporated by reference herein. The information in this Form 8-K, including in the press release furnished as Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchang…
Results of Operations and Financial Condition. E stimated Third Quarter 2025 Acquired In-Process Research and Development (IPR&D) Charges In connection with its previously announced acquisition of Inozyme Pharma, Inc. on July 1, 2025, BioMarin Pharmaceutical Inc. (BioMarin) expects that its reported financial results calculated in accordance with U.S. generally accepted accounting principles (GAAP) and its Non-GAAP financial results for the third quarter of 2025 will include acquired IPR&D ch…
Results of Operations and Financial Condition. On August 4, 2025, BioMarin Pharmaceutical Inc. (the Company) announced financial results for its second quarter ended June 30, 2025. The Company’s press release issued on August 4, 2025 is attached hereto as Exhibit 99.1 and is incorporated by reference herein. The information in this Form 8-K, including in the press release furnished as Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of…
Results of Operations and Financial Condition. On May 1, 2025, BioMarin Pharmaceutical Inc. (the Company) announced financial results for its first quarter ended March 31, 2025. The Company’s press release issued on May 1, 2025 is attached hereto as Exhibit 99.1 and is incorporated by reference herein. The information in this Form 8-K, including in the press release furnished as Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934,…
Results of Operations and Financial Condition. On February 19, 2025, BioMarin Pharmaceutical Inc. (the Company) announced financial results for its fourth quarter ended December 31, 2024. The Company’s press release issued on February 19, 2025 is attached hereto as Exhibit 99.1 and is incorporated by reference herein. The information in this Form 8-K, including in the press release furnished as Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Excha…
Results of Operations and Financial Condition. On October 29, 2024, BioMarin Pharmaceutical Inc. (the Company) announced financial results for its third quarter ended September 30, 2024. The Company’s press release issued on October 29, 2024 is attached hereto as Exhibit 99.1 and is incorporated by reference herein. The information in this Form 8-K, including in the press release furnished as Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchang…
Results of Operations and Financial Condition. On August 5, 2024, BioMarin Pharmaceutical Inc. (the Company) announced financial results for its second quarter ended June 30, 2024. The Company’s press release issued on August 5, 2024 is attached hereto as Exhibit 99.1 and is incorporated by reference herein. The information in this Form 8-K, including in the press release furnished as Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of…
Results of Operations and Financial Condition. On April 24, 2024, BioMarin Pharmaceutical Inc. (the Company) announced financial results for its first quarter ended March 31, 2024. The Company’s press release issued on April 24, 2024 is attached hereto as Exhibit 99.1 and is incorporated by reference herein. The information in this Form 8-K, including in the press release furnished as Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of…